Compositions and methods of treating HIV-1 infections using same
US-9914709-B2 · Mar 13, 2018 · US
US10472334B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10472334-B2 |
| Application number | US-201515122528-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 13, 2015 |
| Priority date | Mar 14, 2014 |
| Publication date | Nov 12, 2019 |
| Grant date | Nov 12, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Compounds suitable for use in providing male contraception, an assay method for identifying such compounds, and methods of providing contraception using the compounds, are provided. In one embodiment, the compounds described herein mimic the binding of anti-EPPIN antibodies to EPPIN, and thus inhibit the forward motility of sperm in humans and other primates. In another embodiment, the compounds described herein inhibit or enhance EPPIN-semenogelin binding, and inhibit forward motility of sperm. The assays described herein identify compounds which inhibit sperm motility, and can be carried out in a high throughput manner, using labeled recombinant EPPIN and semenogelin. The compounds can be used in oral or transdermal compositions to temporarily and reversibly inhibit male fertility. They can also be used in addition to, or in place of, spermicides in spermicidal compositions, such as those used in conjunction with condoms, diaphragms, and spermicidal jellies.
Opening claim text (preview).
The invention claimed is: 1. A method of providing contraception, comprising administering an effective amount of a compound having one of the following formulas: and tautomers, and pharmaceutically-acceptable salts thereof, wherein: R 1 is —CH 2 R 5 , R 2 is H, C 1-8 alkyl, C 1-8 haloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, arylalkyl, alkylaryl, C(X)R 6 or C(X)XR 6 , R 3 is —NHR 7 , —C(X)NHR 7 , —NHC(X)R 7 , —NHC(X)XR 7 , —R 8 , or C(X)R 8 ; R 4 is OR 7 or —C(X)OR 7 , R 5 is H, F, C 1-8 alkyl, C 1-8 haloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, arylalkyl, alkylaryl, —XC(X)XR 6 , C(X)XR 6 , or C(X)R 6 , R 6 and R 7 are H, C 1-8 alkyl, C 1-8 haloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, arylalkyl, or alkylaryl; R 8 is X is O, S, or NR 7 , Y is O, S, NR 7 , or C(R 7 ) 2 , Zj refers to j number of Z substituents, which substituents can be present at any carbon atom on the benzene ring, wherein j is 0, 1 or 2, each Z is, individually, a substituent species selected from the group consisting of C 1-8 alkyl, C 1-8 substituted alkyl, C 2-8 alkenyl, C 2-8 substituted alkenyl, C 3-8 cycloalkyl, C 3-8 substituted cycloalkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, halo, —OR 7 , —N(R 7 ) 2 , —CF 3 , —CN, —NO 2 , —C 2 R 7 , —SR 7 , —N 3 , —C(═O)N(R 7 ) 2 , —NR 7 C(═O)R 7 , —C(═O)R 7 , —C(═O)OR 7 , —OC(═O)R 7 , —O(CR 6 R 7 ) r C(═O)R 7 —, —O(CR 6 R 7 ) r NR 7 C(═O)R 7 , —O(CR 6 R 7 ) r NR 7 SO 2 R 7 , —OC(═O)NR 6 R 7 , —NR 7 C(═O)OR 7 , —SO 2 R 7 , —SO 2 NR 6 R 7 , and —NR 7 SO 2 R 7 , r is an integer from 1 to 6, and n is 0, 1, 2, or 3, the term “substituted” as applied to alkyl, aryl, cycloalkyl and the like refers to the substituents described above, starting with halo and ending with —NR 7 SO 2 R 7 ; and tautomers, and pharmaceutically-acceptable salts thereof, wherein the compounds can exist as single stereoisomers or as mixtures of stereoisomers. 2. The method of claim 1 , wherein haloalkyl is mono-fluoromethyl. 3. The method of claim 1 , wherein R 5 is F, —XC(X)XR—, or C(X)XR 6 . 4. The method of claim 1 , wherein one or more C═X moieties are carbonyl (C═O). 5. A method of providing contraception, comprising an effective amount of a compound having one of the following formulas: 6. A pharmaceutical composition for providing male contraception, comprising an effective amount of a compound of claim 1 . 7. The composition of claim 6 , further comprising a water-soluble lubricant. 8. A compound having one of the following formulas: and tautomers, and pharmaceutically-acceptable salts thereof, wherein: R 1 is —CH 2 R 5 , R 2 is H, C 1-8 alkyl, C 1-8 haloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, arylalkyl, alkylaryl, C(X)R 6 or C(X)XR 6 , R 3 is —NHR 7 , —C(X)NHR 7 , —NHC(X)R 7 , —NHC(X)XR 7 , —R 8 , or C(X)R 8 ; R 4 is OR′ or —C(X)OR 7 , R 5 is H, F, C 1-8 alkyl, C 1-8 haloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, arylalkyl, alkylaryl, —XC(X)XR 6 , C(X)XR 6 , or C(X)R 6 , R 6 and R 7 are H, C 1-8 alkyl, C 1-8 haloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, arylalkyl, or alkylaryl; R 8 is X is O, S, or NR 7 , Y is O, S, NR′, or C(R 7 ) 2 , Zj refers to j number of Z substituents, which substituents can be present at any carbon atom on the benzene ring, wherein j is 0, 1 or 2, each Z is, individually, a substituent species selected from the group consisting of C 1-8 alkyl, C 1-8 substituted alkyl, C 2-8 alkenyl, aryl, alkylaryl, arylalkyl, halo, —OR 7 , —N(R 7 ) 2 , —CF 3 , —CN, —NO 2 , —C 2 R 7 , —SR 7 , —N 3 , —C(═O)N(R 7 ) 2 , —NR 7 C(═O)R 7 , —C(═O)R 7 , —C(═O)OR 7 , —OC(═O)R 7 , —O(CR 6 R 7 ) r C(═O)R 7 —, —O(CR 6 R 7 ) r NR 7 C(═O)R 7 , —O(CR 6 R 7 ) r NR 7 SO 2 R 7 , —OC(═O)NR 6 R 7 , —NR 7 C(═O)OR 7 , —SO 2 R 7 , —SO 2 NR 6 R 7 , and —NR 7 SO 2 R 7 , r is an integer from 1 to 6, and n is 0, 1, 2, or 3, and tautomers, and pharmaceutically-acceptable salts thereof, wherein the compounds can exist as single stereoisomers or as mixtures of stereoisomers. 9. The compound of claim 8 , wherein haloalkyl is mono-fluoromethyl. 10. The compound of claim 8 , wherein R 5 is F, —XC(X)XR 6 , or C(X)XR 6 . 11. The compound of claim 8 , wherein one or more C═X moieties are carbonyl (C═O). 12. A compound of claim 8 , wherein the compound has the formula: or a pharmaceutically acceptable salt, or tautomer thereof. 13. A compound of claim 8 , having one of the following formulas: or a pharmaceutically acceptable salt, or tautomer thereof. 14. A compound of claim 8 , having the formula: or a pharmaceutically acceptable salt, or tautomer thereof.
Masculine contraceptives · CPC title
Two hetero atoms, in positions 3 and 5 · CPC title
with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms · CPC title
having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495}) · CPC title
Ortho-condensed systems · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.